New dual-acting class of antimalarial compounds

Ring-forms and gametocytes of Plasmodium falciparum in human blood.(Wikipedia)

Ring-forms and gametocytes of Plasmodium falciparum in human blood.(Wikipedia)

Researchers from Novartis have reported new dual-acting class of antimalarial compounds with potential to both prevent and treat malaria infections. A new class of antimalarial drug candidates inhibits malaria parasite liver-and blood-stages in malaria models. Most current malaria treatments target blood infections but researchers believe both liver and blood infections need to be treated to eliminate malaria. Over the past decade, Novartis has delivered over 400 million doses of its anti-malarial treatment Coartem without profit, to more than 60 malaria-endemic countries for public sector use.

The findings report on compounds that target both liver and blood infections, attacking the Plasmodium parasite at both stages in its reproduction cycle.

The findings describe how scientists developed a novel assay to determine liver stage activity of candidate small molecules, then used the assay and other tools to identify and optimize a chemical scaffold with activity on both blood- and liver-stage parasites in malaria mouse models. Several other compound classes, also with dual activity, are described and released by Novartis through ChEMBL - Neglected Tropical Disease at www.ebi.ac.uk/chembl­ntd.

"For over a decade, Novartis has engaged in the front ranks of combating malaria, pioneering the not-for-profit supply of our antimalarial treatment Coartem to the public sector of endemic countries," commented Joseph Jimenez, CEO of Novartis. "These new findings further demonstrate our innovative and sustainable research commitment in this important area which has become integral to our corporate strategy for social responsibility."

Scientists from the Novartis Institutes for BioMedical Research (NIBR), through the Genomics Institute of the Novartis Research Foundation (GNF) and the Novartis Institute for Tropical Diseases (NITD), collaborated with the Scripps Research Institute and Swiss Tropical and Public Health Institute. Research was supported by the Wellcome Trust, Singapore Economic Development Board, and Medicines for Malaria Venture.

This is the second new class of antimalarials discovered by the same group in the last two years and holds promise as a next-generation treatment for malaria if confirmed.

"Novartis is committed to the elimination of malaria. Programs with our current anti-malarial treatment have helped save more than one million lives to date, but there remains much to be done," said Mark Fishman, NIBR President. "Concerns of potential future resistance to current medicines, and the need to treat liver forms of malaria, propel our scientists to devise new medicines. The chemical data from this successful study, and the methods of chemical analysis, have all been released to the public domain. Hopefully, such sharing will facilitate broad-based discovery efforts across the globe towards elimination of this disease."

Researchers believe that future antimalarials will need to work against both blood and liver stages to bring us closer to the goal of eliminating malaria globally. The malaria parasite first infects the liver before moving to red blood cells and causing symptoms. However, after clearance in the blood, reservoirs of parasites can linger in the liver causing relapse and hampering efforts toward complete elimination of the disease. Each year there are about 250 million cases of malaria and nearly one million deaths - mostly among children living in Africa.

It is important to develop new classes of treatment that are one step ahead of the parasite should parasite resistance to current therapies occur, according to researchers. In collaboration with research partners, NIBR is working on developing a pipeline of potential new treatment candidates for drug-resistant malaria. Last year’s development of the spiroindolone class, represented by NITD609 , is now in Phase I human clinical trials, with Phase II expected to commence in early 2012.

"Compounds with dual activity are rare among current antimalarials," said Martin Seidel, GNF Institute Director. "The activity of the IZP compound class on liver-stage parasites, if it can be confirmed in clinical trials, gives promise to this class as a first-line therapy for the prevention and treatment of malaria."

According to Elizabeth Winzeler, GNF Department Head and lead investigator, "Little was known about malaria liver stages when we started this work and as a consequence, we didn’t have a good idea about how to approach the problem. Eventually we decided to develop an automated microscopy method to look for compounds that would alter the appearance of the developing liver stages. We are excited that by publishing the full set of compounds active in both blood and liver stages, new targets might be identified."


 


 
 
Jobs on